GuidelinePancreas2013
Consensus guidelines for the management and treatment of neuroendocrine tumors.
Guideline in Pancreas, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 265 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
265 citing papers in PubMed, 4 syntheses or guidelines pooled it, 584 citations in OpenAlex.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Mixed epithelial endocrine neoplasms of the colon and rectum - An evolution over time: A systematic review.World journal of gastroenterology · 2020Pooled it
- Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.JAMA oncology · 2019Pooled it
- Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.Endocrine-related cancer · 2024Trial
- Trial
- Trial
- Review of Haematological Toxicities in Well-Differentiated Neuroendocrine Tumours: A Case Report and Comprehensive Review of the Literature.Journal of clinical medicine · 2026Article
- Should We Continue Liver Transplantation in Spain for Hepatic Metastases from Neuroendocrine Tumors?Journal of clinical medicine · 2026Article
- Endoscopic submucosal dissection with deliberate muscularis propria exposure for curative resection of a large type 1 gastric neuroendocrine tumor: a case report.Frontiers in oncology · 2026Article
- Pancreatic Cystic Lesions in the Older Patient: A Review of Clinical Guidelines and Management.Current gastroenterology reports · 2025Review
- Non-ampullary duodenal neuroendocrine tumours - a tertiary referral centre experience.Scientific reports · 2025Article
- Article
- Gastric neuroendocrine tumors: A review of pathology and updated roadmap to surgical management.World journal of clinical oncology · 2025Review
- Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025Article
- Metachronous Liver Metastasis during Long-term Follow-up after Endoscopic Submucosal Dissection of a Small Rectal Neuroendocrine Neoplasm.Internal medicine (Tokyo, Japan) · 2025Article
- Survival outcomes of local versus radical resection for appendiceal neuroendocrine tumors: a population-based study.Translational cancer research · 2025Article
- Pre-Operative Radiological Diagnosis of Appendiceal Neuroendocrine Neoplasms: Implications for Conservative Management of Acute Appendicitis.ANZ journal of surgery · 2025Article
- Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report.Oncology letters · 2025Article
- Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Evaluated by 18FFDG- PET/CT and Literature ReviewCurrent medical imaging · 2025Review
205 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
Abstract
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.